Skip to main content
Funded Studies

Tanya Simuni, MD

Arthur C. Nielsen Professor of Neurology at Northwestern University

Director, Parkinson's Disease and Movement Disorders Program

Location: Chicago, IL United States

Tanya Simuni, MD, directs the Northwestern University Feinberg School of Medicine’s Movement Disorders Center. She is the principal investigator on many Parkinson’s disease clinical trials and an expert on the design and coordination of multicenter studies. Dr. Simuni is leading a Phase III clinical trial evaluating isradipine as a potential disease-modifying agent in early Parkinson’s, which is supported by the National Institutes of Health. She is also directing the MJFF-supported Phase II study of nilotinib as well as an NINDS-funded study of telemedicine and smart phone technology for long-term assessment of participants in Parkinson’s clinical trials. She serves as the site PI and a member of the Steering Committee for the MJFF Parkinson's Progression Markers Initiative (PPMI) study and is also the site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT) Northwestern Clinical Site (U10). Dr. Simuni is an active member of the Movement Disorders Society, the International Association of Parkinsonism and Related Disorders, the American Academy of Neurology, American Neurological Association, the Parkinson’s Study Group, and REM Behavior Disorders Study Group. She earned her medical degree from Leningrad Medical School and completed her residency and fellowship at Temple University Hospital.

Associated Grants

  • Phase IIa Safety and Tolerability Trial of Nilotinib in People with Parkinson's Disease


  • Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease


  • High resolution diffusion tensor MRI imaging as a biomarker of Parkinson Disease diagnosis and disease progression


  • Biomarkers of Pioglitazone Effects in Parkinson's Disease (BioPEP)


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.